New daily pill aims to shield kids from TB
NCT ID NCT07124559
First seen Feb 03, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests a 28-day daily pill (rifapentine plus isoniazid) to prevent tuberculosis (TB) in children under 13 years old, including those with HIV. About 144 children will join, split into groups based on HIV status, and be followed for 24 weeks. The goal is to find the best dose and ensure the treatment is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor-Uganda (Site ID: 31798)
Kampala, Uganda
-
Chiangrai Prachanukroh Hospital (Site ID: 5116)
Chiang Rai, 57000, Thailand
-
Gaborone (Site ID: 12701)
Gaborone, Botswana
-
Harare Family Care (Site ID: 31890)
Belgravia, Harare, Zimbabwe
-
Kenya Medical Research Institute, Walter Reed Project Clinical Research Center (Site ID: 5121)
Kericho, 20200, Kenya
-
Les Centres GHESKIO (Site ID: 30022)
Port-au-Prince, HT-6110, Haiti
-
MU-JHU Care Limited (Site ID: 5126)
Kampala, Uganda
-
Molepolole (Site ID: 12702)
Gaborone, Botswana
-
Seke North (Site ID: 30306)
Belgravia, Harare, Zimbabwe
-
Siriraj Hospital, Mahidol University (Site ID: 5115)
Bangkok, Bangkoknoi, 10700, Thailand
-
St Mary's (Site ID: 30303)
Chitungwiza, Zimbabwe
Conditions
Explore the condition pages connected to this study.